WO2000077167A3 - Systeme de ciblage par vecteur d'amplicon du virus herpes simplex et technique d'utilisation - Google Patents

Systeme de ciblage par vecteur d'amplicon du virus herpes simplex et technique d'utilisation Download PDF

Info

Publication number
WO2000077167A3
WO2000077167A3 PCT/US2000/016050 US0016050W WO0077167A3 WO 2000077167 A3 WO2000077167 A3 WO 2000077167A3 US 0016050 W US0016050 W US 0016050W WO 0077167 A3 WO0077167 A3 WO 0077167A3
Authority
WO
WIPO (PCT)
Prior art keywords
herpes simplex
simplex virus
same
targeting system
vector targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/016050
Other languages
English (en)
Other versions
WO2000077167A2 (fr
Inventor
Matthew A Spear
Xandra O Breakefield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
University of California Berkeley
University of California San Diego UCSD
Original Assignee
General Hospital Corp
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, University of California Berkeley, University of California San Diego UCSD filed Critical General Hospital Corp
Priority to EP00938260A priority Critical patent/EP1444353A2/fr
Publication of WO2000077167A2 publication Critical patent/WO2000077167A2/fr
Anticipated expiration legal-status Critical
Publication of WO2000077167A3 publication Critical patent/WO2000077167A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16645—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des vecteurs d'amplicon du virus herpès simplex (HSV), et en particulier, des vecteurs d'amplicon HSV-1, qui ont été génétiquement modifiés et utilisés seuls ou avec un virus HSV génétiquement modifié en conséquence, de façon à cibler un type de cellule sélectionné, tel que des cellules néoplastiques. Cette invention concerne aussi des techniques d'utilisation de ces vecteurs destinés à cibler une cellule, de façon à traiter un état pathologique, tel qu'un cancer.
PCT/US2000/016050 1999-06-11 2000-06-12 Systeme de ciblage par vecteur d'amplicon du virus herpes simplex et technique d'utilisation Ceased WO2000077167A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP00938260A EP1444353A2 (fr) 1999-06-11 2000-06-12 Systeme de ciblage par vecteur d'amplicon du virus herpes simplex et technique d'utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13896399P 1999-06-11 1999-06-11
US60/138,963 1999-06-11

Publications (2)

Publication Number Publication Date
WO2000077167A2 WO2000077167A2 (fr) 2000-12-21
WO2000077167A3 true WO2000077167A3 (fr) 2004-05-06

Family

ID=22484469

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/016050 Ceased WO2000077167A2 (fr) 1999-06-11 2000-06-12 Systeme de ciblage par vecteur d'amplicon du virus herpes simplex et technique d'utilisation

Country Status (2)

Country Link
EP (1) EP1444353A2 (fr)
WO (1) WO2000077167A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US8216564B2 (en) 2002-05-02 2012-07-10 Ramot At Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5501979A (en) * 1989-02-01 1996-03-26 The General Hospital Corporation Herpes simplex virus type I expression vector
US5869331A (en) * 1992-11-20 1999-02-09 University Of Medicine & Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851826A (en) * 1995-07-26 1998-12-22 Children's Medical Center Corporation Helper virus-free herpesvirus vector packaging system
AU8605598A (en) * 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5501979A (en) * 1989-02-01 1996-03-26 The General Hospital Corporation Herpes simplex virus type I expression vector
US5869331A (en) * 1992-11-20 1999-02-09 University Of Medicine & Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of EP1444353A4 *
TAL-SINGER ET AL.: "Interaction of herpes simplex virus glycoprotein gC with mammalian cell surface molecules", JOURNAL OF VIROLOGY, vol. 69, no. 7, July 1995 (1995-07-01), pages 4471 - 4483, XP000946705 *
WANG ET AL.: "A hybrid herpesvirus infectious vector based on epstein-barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo", JOURNAL OF VIROLOGY, vol. 70, December 1996 (1996-12-01), pages 8422 - 8430, XP000946704 *

Also Published As

Publication number Publication date
EP1444353A4 (fr) 2004-08-11
WO2000077167A2 (fr) 2000-12-21
EP1444353A2 (fr) 2004-08-11

Similar Documents

Publication Publication Date Title
WO1997021826A3 (fr) Systemes de vecteurs adenoviraux et de lignees cellulaires complementaires
MX9800145A (es) Vectores y virales de tejido especifico.
WO1997013866A3 (fr) Vecteurs de recombinaison du virus herpetique pour une expression des cellules neuronales
CA2192442A1 (fr) Systemes de vecteurs adenoviraux et lignees cellulaires complementaires
DE69738709D1 (de) Herpes simplex virusstaemme
GB2136814B (en) Dna vectors
WO2000054813A3 (fr) Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prévention des maladies de l'oeil
IL110284A0 (en) Viral vectors and their use in gene therapy
WO2000012726A3 (fr) Heparinases a conception rationnelle derivees de l'heparinase i et ii
ZA942778B (en) Recombinant viruses, and their preparation and use in gene therapy.
ZA971159B (en) Target cell-specific vectors for inserting genes into cells, pharmaceuticals comprising such vectors and their use.
IL181695A0 (en) Methods for cultivating cells and propagating viruses
WO2003068809A8 (fr) Complexe du virus herpes simplex
EP0085548A3 (fr) Vecteurs de clonage
WO1995034651A3 (fr) Recepteurs du facteur2 liberant la corticotropine
AU5318496A (en) Adenovirus vectors for gene therapy
FR2710074B1 (fr) Gène GRB3-3, ses variants et leurs utilisations.
WO2000077167A3 (fr) Systeme de ciblage par vecteur d'amplicon du virus herpes simplex et technique d'utilisation
EP0115173A3 (fr) Vecteurs de clonage pour streptomyces
WO1998049333A3 (fr) Cassette d'expression genetique eucaryote et ses utilisations
EP1144666A3 (fr) Systeme d'expression du baculovirus
WO2002064025A3 (fr) Traitement du cancer par inhibition de l'activite de l'atf2
WO2002057412A3 (fr) Promoteurs de plante et leurs methodes d'utilisation
AU3804997A (en) Vectors for inhibiting HIV and tumor growth
AU4306996A (en) Encapsidation cell lines for the transcomplementation of defective retroviral vectors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000938260

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWP Wipo information: published in national office

Ref document number: 2000938260

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000938260

Country of ref document: EP